

# 2012 Oncology Service Line Goals and Accomplishments



# 2012 Program goals and outcomes

## Quality and Service

- Seek NAPBC accreditation by December 31, 2012
  - Application was accepted; visit date set for April 29, 2013
- Successful ACoS reaccreditation visit with <3 deficiencies
  - Survey completed June 11, 2012: 3 year accreditation with 4 Commendations:
    - Standard 3.3 Abstracting timeframe
    - Standard 4.6 CAP guidelines
    - Standard 6.2 Prevention and early detection
    - Standard 8.2 Cancer-related quality improvements
- Radiation Patients are offered psychosocial screening for distress upon admission to services
  - Currently using NCCN distress screening tool in radiation oncology
    - Screen upon admission and rescreen after interventions, individuals who score >4 and at critical times during treatment course


- Dietitian services are offered to all head and neck cancer patients during the course of radiation
  - Program implemented to assess all head and neck patients however program suspended in September due to staff turnover. New staff will begin February 2013
  - Cancer navigation services on average provided to 20 patients/month by navigation nurse
- 92<sup>nd</sup> percentile overall patient satisfaction within the cancer center and infusion center (see next two slides)

# Mean Trends

# Patient Satisfaction Outpatient Services – Infusion Center

Trinity Rock Island

Overall




SIC



# Mean Trends

## Patient Satisfaction Outpatient Services – Radiation Oncology Trinity Rock Island

Overall



ONC



# Growth

- Expand radiation oncology with the addition of a TrueBeam replacement linear accelerator; implement stereotactic program-treat first SRS patient by December 2012
  - TrueBeam operational July 24, 2012
  - Aria (radiation EMR) operational July 24, 2012; however not paperless-interfaces planned in 2013
  - Eclipse treatment planning system implemented November 2012
  - SRS program to begin 1<sup>st</sup> quarter 2013

- Develop programs to address community health needs assessment oncology gaps in care: lung cancer deaths and mammogram screening
  - Developed High Risk Lung Cancer screening program
    - Program soft launch August 2012
    - Internal marketing October 2012
    - Marketing plan developed but not fully implemented
      - Currently no patients enrolled
  - Breast Program (see next 2 slides)



Moline • Rock Island • Bettendorf • Muscatine

# Cancer Division Scorecard

Cancer Services

Breast 2012

Quarter

Indicator			Source of Data	Reporting Frequency	Target Target Source	4th 2011	1st 2012	2nd 2012	3rd 2012	Current
<b>Demonstrably Better Quality</b>										
<b>Ind.</b>	<b>NQMBC - required measures</b>				<b>75th - Midwest</b>					
1	Mammography Call Back Rate	MRS	bi-annually	6.50% NQMBC	10.52%	18.57	12.67	12.52	12.06	
<b>Imaging Timeliness of Care</b>										
2	Time between screening mammogram and diagnostic mammogram	MRS internal stats	Quarterly	3.00 b. days NQMBC	3.87	4.55	4.6	2.43	5.05	
3	Time between diagnostic mammogram and needle/core biopsy	MRS internal stats	Quarterly	4.00 b. days NQMBC	12.86	13.18	9.31	13.94	10.53	
<b>Surgical Timeliness of Care</b>										
4	Time between needle biopsy and definitive surgery	internal stats	Quarterly	b.days						
<b>Pathology Timeliness of Care</b>										
5	Time between core breast biopsy and pathology results	internal stats	Quarterly	1.25 b. days NQMBC		2.31	2.34	2.39	2.4	
<b>Std.</b>	<b>Pathology Report Completeness</b>									
2.7	CAP committee guidelines are followed	Registry data	Quarterly	90%	96.2%	91.0%	88.0%	98.0%		



Std.	CoC - required measures										
4.4		Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer	Registry Data	Quarterly	≥ 90% CoC - CP3R	89.8%					2010
4.4		Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor-negative breast cancer	Registry Data	Quarterly	≥ 90% CoC - CP3R	93.8%					2010
4.4		Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer	Registry Data	Quarterly	≥ 90% CoC - CP3R	88.5%					2010

Std.	Surgical Measures										
2.3		Breast conservation rate (Stage 0, 1,2)	Registry Data	Quarterly	>60% when appropriate		56%	59%	66%		71%
2.4		Sentinal node biopsy (Stage 1,2)	internal stats	Quarterly	95% when appropriate		56%	61%	72%		100%
2.9		Needle Core biopsy rate	Registry data	Quarterly	95% when appropriate		92%	90%	88%		90%
2.18		Reconstruction consultation	internal stats	Quarterly	100% when appropriate		22%	69%	71%		40%
3.2		Clinical Trial accrual	Registry Data	Annual	2% (5 cases)		19 cases	2	0		

Risk Assessment											
2.16		Genetic referrals - number of breast pt. seen for genetic consult	internal stats	Quarterly	total number		0	0			

Financial Performance										
						2012 total				
		Screening Volumes	internal stats	Quarterly		13642	3485	3284	3156	3717
		Total volumes (screening & diagnostic)	internal stats	Quarterly		15345	3948	3707	3561	4129
						2010	2011	2012		
		Total Breast Cancer Cases (Incidence Data)	Cancer Registry	Annual		185	237			

Patient Satisfaction						1st Q	2nd Q	3rd Q	4th Q
7		Overall patient satisfaction with Mammography	Press Ganey	Quarterly	92nd %tile	77%	76%	31%	62%
		Likelihood to recommend	Press Ganey	Quarterly	92nd %tile	70%	79%	37%	57%
		Target and above							
		74th - 50th							
		49th or below							

# Community

- Promote community health and wellness through screening, detection and education programs; 2 screening events per year and 2 community education events (see next slide)
- Implement Breast Cancer Survivor plan by December 31, 2012 (not achieved)

# IBBCP Summary Statistics

## 1/01/12-12/31/12

Category	Patients			Screening Svcs		Cancers/Precancerous Conditions			
	Total	New	Est	Mamm	Pap	Invas Breast	In Situ Breast	Invas Cerv	CIN III
<b>AGE Range</b>									
Under 35	33	18	15	0	12				
35-39	67	14	53	3	15				
40-49	229	42	187	117	82		1		
50 +	171	38	133	340	99	2			1
<b>Total</b>	<b>500</b>	<b>112</b>	<b>388</b>	<b>460</b>	<b>208</b>	<b>2</b>	<b>1</b>		<b>1</b>

<b>RACE/Ethnicity</b>									
White	424	92	332	290	180	2	1		
Hispanic	124	28	96	83	56				
Black	59	13	46	38	23				1
Asian	11	4	7	9	2				
Am Indian/AK Native									
Hawaiian/Oth Pac Is									
Other	6	3	3	3	3				

Invasive Breast

Stage II (1)

Stage IV (1)

# Community Activities

## 2012

Numerous Health Fairs throughout the area:

RIA Health Fair, Day of Dance, City of Moline, John Deere Health Fairs, Muscatine Health Fair, Jumer's Casino Fair, Girls' Night Out, Davenport School system, Holy Family Church, Black Hawk college,

Witness Project Programs

National Women's Health Week

King Center Days

East Moline Transportation

Didactic Presentations

*Frankly Speaking About Cancer* – Gilda's Club

*Dealing with a Cancer Diagnosis* – Chaplains

*Cancer Care at Trinity* – TCON

*Smoke Free That's Me* – 6 schools (415 2<sup>nd</sup> & 4<sup>th</sup> grade students)

*Navigation – What is it?* – Cancer Registrars  
National Convention and Trinity Radiology

Cancer Theme Events/Partnerships

- Stylin' Against Breast Cancer
- ACS Look Good, Feel Better
- Quad-Cities Breast Cancer and Lymphedema Support Group
- Gilda's (On Site) Club
- Relay for Life
- Making Strides Against Breast Cancer
- Pink PJ Party
- Girls' Night Out
- Conquering Cancer Through Christ Support Group
- Augustanna College Melanoma Walk
- Augustanna Employee skin cancer presentation
- Living Proof Exhibit and Art Therapy Classes

# Cancer Screening

- Skin Screening
  - 75 individuals screened by dermatologists
  - April and October
    - 12 precancerous actinosis keratosis
    - 3 dysplastic nevus
    - 3 squamous cell cancers
    - 5 basal cell cancers
  
- Prostate Screening
  - 242 men (screening criteria: <75, no prostate cancer history and not under care of urologist)
    - 97 men screened Sept. 11 at Bettendorf
    - 145 men screened Sept. 13 at Moline
      - 22 men were diagnosed with an abnormal exam and/or PSA

# Research

## Cancer Prevention Studies

- **8 New studies were opened in Cancer research**
- **Total studies open at TMC for Cancer research 58 with 40 currently open to accrual**
- **3.0 % accrual rate**
- **30 people were entered on clinical trials**
  - 8 cancer treatment
  - 2 symptom management
  - Prevention/LEAP
    - 2 Enrolled
  - Blood/Tissue/Genetic Repository 18 accrued

## Vault preparation for the TrueBeam



## TrueBeam prior to commissioning

